FIREHAWK®

Healthcare Professionals Cardiovascular Percutaneous Coronary Intervention Firehawk

Firehawk® Rapamycin Target Eluting Coronary Stent System Features

Firehawk Safety 690x300


Clinical Evidence

TARGET All Comers Trial1

  • 1,656 Patients from 20 sites in Europe
  • 1:1 RCT Real World open-label, non-inferiority trial
  • Primary endpoint: TLF @12 months
  • Confirms that the Firehawk®, a low dose sirolimus eluting biodegradable polymer DES, is safe
    and effective across a broad spectrum of patient and lesion complexity
Firehawk Firehawk2 1

Prob/Definite stent Thrombosis at 1 year

  • 1-year Stent thrombosis rate result shows non-inferiority than Durable-Polymer DES
  • Shows proven safety in all comers population
Firehawk Firehawk3 1 2

Product Specification

Stent Material:

L605 CoCr

Polymer:

PLA, 100% Biodegradable

Drug:

Rapamycin (Sirolimus)

Drug Dosage:

0.3 µg/mm2

Strut Thickness:

86µm (Ø2.25mm - 3.0mm)
96.5µm (Ø3.5mm - 4.0mm)

Nomial Pressure:

10 atm

Rated Burst Pressure:

16 atm (Ø2.25mm - 3.5mm)
14 atm (Ø4.0mm)

Mean Recoil:

3.4%

Mean Foreshortening:

1.95% - 5.30%

Ordering Information

Length /Ø13mm16mm18mm21mm23mm26mm29mm31mm33mm35mm38mm
2.25mmRV2213RV2216RV2218RV2221RV2223RV2226RV2229----
2.5mmRV2513RV2516RV2518RV2521RV2523RV2526RV2529RV2531RV2533--
2.75mmRV2713RV2716RV2718RV2721RV2723RV2726RV2729RV2731RV2733RV2735RV2738
3.0mmRV3013RV3016RV3018RV3021RV3023RV3026RV3029RV3031RV3033RV3035RV3038
3.5mmRV3513RV3516RV3518RV3521RV3523RV3526RV3529RV3531RV3533RV3535RV3538
4.0mmRV4013RV4016RV4018RV4021RV4023RV4026RV4029RV4031RV4033RV4035RV4038

1 Lansky, A., Wijns, W., Xu, B.,…Baumbach, A.(2018). Targeted therapy with a localised abluminal groove, low-dose sirolimus-eluting, biodegradable polymer coronary stent (TARGET All Comers): a multicentre, open-label, randomised non-inferiority trial. Lancet. Doi: 10.1016/S0140-6736(18)31649-0